BR112014000358A2 - (1r,4r)-6'-fluoro-n,n-dimetil-4-fenil-4',9'-diidro-3'h-espiro[cicloexano-1,1'-pirano[3,4,b]indol]-4-amina cristalina - Google Patents

(1r,4r)-6'-fluoro-n,n-dimetil-4-fenil-4',9'-diidro-3'h-espiro[cicloexano-1,1'-pirano[3,4,b]indol]-4-amina cristalina

Info

Publication number
BR112014000358A2
BR112014000358A2 BR112014000358A BR112014000358A BR112014000358A2 BR 112014000358 A2 BR112014000358 A2 BR 112014000358A2 BR 112014000358 A BR112014000358 A BR 112014000358A BR 112014000358 A BR112014000358 A BR 112014000358A BR 112014000358 A2 BR112014000358 A2 BR 112014000358A2
Authority
BR
Brazil
Prior art keywords
spiro
dihydro
cyclohexane
fluoro
dimethyl
Prior art date
Application number
BR112014000358A
Other languages
English (en)
Inventor
Michael Gruss
Stefan Kluge
Stefan Prühs
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Publication of BR112014000358A2 publication Critical patent/BR112014000358A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)

Abstract

abstract: the present invention relates to crystalline forms of (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'l-l-spiro[cyclohexane-1,1 '-pyrano[3,4,b]indol]-4-amine, pharmaceutical compositions and medicaments comprising these modifications, the use of these modifications as well as to a process for the enrichment of them __________________________________ tradução do resumo resumo patente de invenção: "(1r,4r)-6’-fluoro-n,n-dimetil-4-fenil-4’,9’-diidro-3’h-espiro[cicloexano-1,1’-pirano[3,4,b]indol]-4-amina cristalina". a presente invenção refere-se às formas cristalinas de (1r,4r)-6’-fluoro-n,n-dimetil-4-fenil-4’,9’-diidro-3’h-espiro[cicloexano-1,1’-pirano-[3,4,b]indol]-4-amina, composições farmacêuticas e medicamentos compre-endendo estas modificações, o uso destas modificações, assim como a um processo para o seu enriquecimento.
BR112014000358A 2011-07-08 2012-07-06 (1r,4r)-6'-fluoro-n,n-dimetil-4-fenil-4',9'-diidro-3'h-espiro[cicloexano-1,1'-pirano[3,4,b]indol]-4-amina cristalina BR112014000358A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11005587 2011-07-08
PCT/EP2012/002839 WO2013007361A1 (en) 2011-07-08 2012-07-06 Crystalline (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine

Publications (1)

Publication Number Publication Date
BR112014000358A2 true BR112014000358A2 (pt) 2017-01-10

Family

ID=46717800

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014000358A BR112014000358A2 (pt) 2011-07-08 2012-07-06 (1r,4r)-6'-fluoro-n,n-dimetil-4-fenil-4',9'-diidro-3'h-espiro[cicloexano-1,1'-pirano[3,4,b]indol]-4-amina cristalina

Country Status (23)

Country Link
US (2) US8618156B2 (pt)
EP (2) EP3235821B1 (pt)
JP (2) JP6276689B2 (pt)
CN (2) CN106939005A (pt)
AR (1) AR087081A1 (pt)
AU (2) AU2012283449B2 (pt)
BR (1) BR112014000358A2 (pt)
CA (1) CA2841032C (pt)
CY (1) CY1120525T1 (pt)
DK (2) DK3235821T3 (pt)
EA (1) EA026750B1 (pt)
ES (1) ES2641299T3 (pt)
HR (1) HRP20170968T1 (pt)
HU (1) HUE033043T2 (pt)
IL (1) IL230331B (pt)
LT (1) LT2729470T (pt)
MX (1) MX2014000297A (pt)
PL (1) PL2729470T3 (pt)
PT (1) PT2729470T (pt)
RS (1) RS56343B1 (pt)
SI (1) SI2729470T1 (pt)
TW (1) TWI585092B (pt)
WO (1) WO2013007361A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106939005A (zh) * 2011-07-08 2017-07-11 格吕伦塔尔有限公司 晶态的（1r,4r）‑6’‑氟‑N,N‑二甲基‑4‑苯基‑4’,9’‑二氢‑3’H‑螺[环己烷‑1,1’‑吡喃并[3,4,b]吲哚]‑4‑胺
AU2016208779B2 (en) 2015-01-23 2020-11-12 Grunenthal Gmbh Cebranopadol for treating pain in subjects with impaired hepatic and/or impaired renal function
EP3253374B1 (en) 2015-02-02 2018-11-28 ratiopharm GmbH Composition comprising cebranopadol in a dissolved form
WO2017148595A1 (en) 2016-02-29 2017-09-08 Grünenthal GmbH Titration of cebranopadol
CN112313202A (zh) * 2019-05-21 2021-02-02 江苏众强药业有限公司 曲前列尼尔钠盐新晶型及制备方法
CN112254496A (zh) * 2020-09-25 2021-01-22 榆林学院 一种煤泥收集装置

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10252667A1 (de) * 2002-11-11 2004-05-27 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
DE102005016460A1 (de) * 2005-04-11 2006-10-19 Grünenthal GmbH Spriocyclische Cyclohexanderivate zur Behandlung von Substanzabhängigkeit
DE102006033109A1 (de) * 2006-07-18 2008-01-31 Grünenthal GmbH Substituierte Heteroaryl-Derivate
DE102006046745A1 (de) 2006-09-29 2008-04-03 Grünenthal GmbH Gemischte ORL1/µ-Agonisten zur Behandlung von Schmerz
RU2631481C2 (ru) * 2010-08-04 2017-09-22 Грюненталь Гмбх ЛЕКАРСТВЕННАЯ ДОЗИРОВАННАЯ ФОРМА, КОТОРАЯ СОДЕРЖИТ 6'-ФТОР-(N-МЕТИЛ-ИЛИ N, N-ДИМЕТИЛ-)-4-ФЕНИЛ-4', 9'-ДИГИДРО-3' Н-СПИРО[ЦИКЛОГЕКСАН-1, 1'-ПИРАНО[3, 4, b] ИНДОЛ]-4-АМИН ДЛЯ ЛЕЧЕНИЯ НОЦИЦЕПТИВНОЙ БОЛИ
CN106939005A (zh) * 2011-07-08 2017-07-11 格吕伦塔尔有限公司 晶态的（1r,4r）‑6’‑氟‑N,N‑二甲基‑4‑苯基‑4’,9’‑二氢‑3’H‑螺[环己烷‑1,1’‑吡喃并[3,4,b]吲哚]‑4‑胺

Also Published As

Publication number Publication date
AU2017204572B2 (en) 2018-05-24
HRP20170968T1 (hr) 2017-09-22
LT2729470T (lt) 2017-08-25
EP2729470A1 (en) 2014-05-14
AU2012283449A8 (en) 2014-03-27
CN103649094A (zh) 2014-03-19
US8618156B2 (en) 2013-12-31
CA2841032A1 (en) 2013-01-17
DK2729470T3 (en) 2017-09-11
WO2013007361A9 (en) 2013-12-27
DK3235821T3 (da) 2020-04-20
US8765800B2 (en) 2014-07-01
ES2641299T3 (es) 2017-11-08
AR087081A1 (es) 2014-02-12
CY1120525T1 (el) 2019-07-10
IL230331B (en) 2018-11-29
AU2017204572A1 (en) 2017-07-27
WO2013007361A8 (en) 2013-04-04
AU2012283449A1 (en) 2014-02-20
JP2014518226A (ja) 2014-07-28
EP3235821B1 (en) 2020-04-08
AU2012283449B2 (en) 2017-04-06
EA201400120A1 (ru) 2014-06-30
JP6559165B2 (ja) 2019-08-14
EA026750B1 (ru) 2017-05-31
JP6276689B2 (ja) 2018-02-07
HUE033043T2 (hu) 2017-11-28
WO2013007361A1 (en) 2013-01-17
TW201311694A (zh) 2013-03-16
CN106939005A (zh) 2017-07-11
TWI585092B (zh) 2017-06-01
PL2729470T3 (pl) 2017-11-30
PT2729470T (pt) 2017-10-02
SI2729470T1 (sl) 2017-10-30
CA2841032C (en) 2020-12-15
US20130012563A1 (en) 2013-01-10
CN103649094B (zh) 2017-05-24
EP2729470B1 (en) 2017-06-21
RS56343B1 (sr) 2017-12-29
MX2014000297A (es) 2014-01-31
JP2017081981A (ja) 2017-05-18
EP3235821A1 (en) 2017-10-25
US20130231381A1 (en) 2013-09-05

Similar Documents

Publication Publication Date Title
BR112014000358A2 (pt) (1r,4r)-6'-fluoro-n,n-dimetil-4-fenil-4',9'-diidro-3'h-espiro[cicloexano-1,1'-pirano[3,4,b]indol]-4-amina cristalina
PL2809307T3 (pl) Plaster farmaceutyczny do podawania przezskórnego (1r,4r)-6'-fluoro-N,N-dimetylo-4-fenylo-4',9'-dihydro-3'H-spiro[cykloheksano-1,1'-pirano[3,4-b]indolo]-4-aminy
IL235654A0 (en) A pharmaceutical preparation containing (1r, 4r) - 6' - fluoro - n, n - dimethyl - 4 - phenyl - 4', 9' - dihydro - 3'h - spiro [cyclohexane - 1, 1' - pyrano [3, 4 ,b] Indole] – 4 – amine and anticonvulsant drug
BR112015022509A2 (pt) forma cristalina de cis-(e)-4-(3-fluorofenil)-2',3',4',9'-tetra-hidro-n,n-dimetil-2'-(1-oxo-3-fenil-2-propenil)-espiro[ciclohexano-1,1'[1h]-pirido[3,4-b]indol]-4-amina cristalina
IL235658A0 (en) Pharmacy device containing (1r, 4r) - 6' - fluoro - n, n - dimethyl - 4 - phenyl - 4', 9' - dihydro - 3'h - spiro [cyclohexane - 1, 1' - pyrano [3, 4 ,b] indole] – 4 – amine and gabapentinoid
BR112014014202A2 (pt) formas sólidas de cloridrato de (1r,4r)-6'-fluoro-n,n-dimetil-4-fenil-4',9'-dihidro-3'h-espiro-[ciclohexano-1,1'-pirano[3,4,b]indol]-4-amina
BR112014014168A2 (pt) processo para a preparação de (1r,4r)-6'-fluoro-(n,n-dimetil e n-metil)-4-fenil-4',9'-dihidro-3'h-espiro[ciclohexano-1,1'-pirano-[3,4,b]indol]-4-amina
HRP20171843T1 (hr) Farmaceutski pripravak koji sadrži (1r,4r)-6'-fluoro-n,n-dimetil-4-fenil-4',9'-dihidro-3'h-spiro[cikloheksan-1,1'-pirano [3,4,b]indol]-4-amin i meloksikam
BR112014014164A2 (pt) formas sólidas de (1r,4r)-6'-fluoro-n,n-dimetil-4-fenil-4',9'-dihidro-3'h-espiro-[ciclohexano-1,1'-pirano[3,4,b]indol]-4-amina e ácido sulfúrico
IL235657B (en) Pharmacy device containing (1r, 4r) - 6' - fluoro - n, n - dimethyl - 4 - phenyl - 4', 9' - dihydro - 3'h - spiro [cyclohexane - 1, 1' - pyrano [3, 4 ,b] indole] – 4 – amine and antidepressants
HUE035930T2 (hu) (1R,4R)-6'-fluor-N,N-dimetil-4-fenil-4',9'-dihidro-3'H-spiro [ciklohexán-l,l'-pirano-[3,4,B]indol]-4-amint és acetilszalicilsavat tartalmazó gyógyászati készítmény
BR112014028561A2 (pt) composição farmacêutica compreendendo (1r,4r )-6'-fluoro-n, n-dimetil-4-fenil-4', 9'-di-hidro-3'h-espiro[ciclo-hexano-1,1'-pirano-[3,4,b]indol]-4-amina e paracetamol ou propacetamol

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2627 DE 11-05-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.